Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16NO.Cl |
Molecular Weight | 201.693 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CC[N+](C)(C)C1=CC(O)=CC=C1
InChI
InChIKey=BXKDSDJJOVIHMX-UHFFFAOYSA-N
InChI=1S/C10H15NO.ClH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H
DescriptionSources: http://www.rxlist.com/enlon-drug.htm
Sources: http://www.rxlist.com/enlon-drug.htm
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Originator
Sources: https://www.google.com/patents/US2647924
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
|||
Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397501 |
|||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8109771 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
|||
Preventing | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
56.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
84.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Myasthenia syndrome during penicillamine treatment. | 1975 Jun 28 |
|
Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. | 1977 |
|
[Prognostic factors and outcome of thymectomy in 80 cases of myasthenia gravis]. | 2001 Apr |
|
Electrogastrography: a non-invasive measurement of gastric function. | 2001 Apr-Jun |
|
[A patient with facioscapulohumeral muscular dystrophy accompanied by myasthenia gravis]. | 2001 Apr-May |
|
Focal myopathy mimicking posterior interosseous nerve syndrome. | 2001 Jul |
|
Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase? | 2001 Jun 26 |
|
Laryngeal myasthenia gravis: report of 40 cases. | 2001 Mar |
|
Interaction of edrophonium with muscarinic acetylcholine M2 and M3 receptors. | 2001 May |
|
Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much? | 2001 Sep |
|
Respiratory failure due to vocal cord paresis in myasthenia gravis. | 2002 |
|
Clinical, electrophysiological and immunological remissions after thymectomy in myasthenia gravis. | 2002 Apr |
|
Purification of soluble acetylcholinesterase from Japanese quail brain by affinity chromatography. | 2002 Feb |
|
Effects of the anticholinesterase edrophonium on spectral analysis of heart rate and blood pressure variability in humans. | 2002 Jan |
|
Oxyaniliniums as acetylcholinesterase inhibitors for the reversal of neuromuscular block. | 2002 Jan 21 |
|
[Thymectomy in juvenile myasthenia gravis]. | 2002 Jul 16-31 |
|
[What to do in case of acquired ptosis]. | 2002 Mar |
|
The effect of edrophonium on autonomic outflow. | 2002 Mar |
|
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. | 2002 Nov |
|
A comparison of the chronotropic and dromotropic actions between adenosine triphosphate and edrophonium in patients undergoing coronary artery bypass graft surgery. | 2002 Oct |
|
Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase. | 2003 Apr |
|
[Comparison between idiopathic achalasia and achalasia caused by Chagas' disease: a review on the publications about the subject]. | 2003 Apr-Jun |
|
[Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody]. | 2003 Aug |
|
Natural monomeric form of fetal bovine serum acetylcholinesterase lacks the C-terminal tetramerization domain. | 2003 Dec 30 |
|
Esophageal manometry in patients with clinical symptoms mimicking esophageal origin: a hospital-based ten-year experience. | 2003 Jan |
|
Positive tensilon test and intracranial tumor: a case report. | 2003 Jul |
|
Chiropractic care of a pediatric patient with myasthenia gravis. | 2003 Jul-Aug |
|
Endplate dysfunction causing respiratory failure in a patient with prior paralytic poliomyelitis. | 2003 Mar |
|
Utility of ambulatory 24-hour esophageal pH and motility monitoring in noncardiac chest pain: report of 90 patients and review of the literature. | 2003 May |
|
Antinociception of intrathecal cholinesterase inhibitors and cholinergic receptors in rats. | 2003 Oct |
|
Myasthenia gravis in childhood. | 2004 |
|
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. | 2004 Feb |
|
Does acetylcholinesterase inhibition affect catecholamine secretion by adrenomedullary cells? | 2004 Jul |
|
[A case of transient left ventricular ballooning ("Takotsubo"-shaped cardiomyopathy) developed during plasmapheresis for treatment of myasthenic crisis]. | 2004 Mar |
|
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. | 2004 Mar |
|
Immunological and electrophysiological investigations of severe ptosis after bone marrow transplantation. | 2004 Sep |
|
Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. | 2004 Sep 11 |
|
Advances in the diagnosis of neuromuscular junction disorders. | 2005 Aug |
|
Edrophonium-induced right ventricular outflow tract tachycardia. | 2005 Jan |
|
Clinical utility of videofluorography with concomitant Tensilon administration in the diagnosis of bulbar myasthenia gravis. | 2005 May |
|
MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence. | 2005 May |
|
Management of myasthenia gravis. | 2005 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rxlist.com/enlon-drug.htm
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8
Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated.
Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions.
For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C47507
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
DTXSID1022978
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
4759
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
100000080513
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
DBSALT000475
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
187
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
EDROPHONIUM CHLORIDE
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless.Solubility: Soluble in 0.5 parts of water and in 5 parts of ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Diagnostic agent.Storage: Edrophonium chloride should be kept in a well-closed container, protected from light.Requirements: Definition. Edrophonium chloride contains not less than 98.5% and not more than 101.0% of C10H16ClNO, calculated withreference to the dried substance. | ||
|
204-138-4
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
QO611KSM5P
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL1104
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
116-38-1
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
1234001
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
m4834
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
8307
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
SUB06461MIG
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
759577
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
QO611KSM5P
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | |||
|
3754
Created by
admin on Sat Dec 16 16:13:50 GMT 2023 , Edited by admin on Sat Dec 16 16:13:50 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SUBSTANCE RECORD